A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Status:
Completed
Trial end date:
2017-10-28
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, multicenter study is to assess the long term safety and
efficacy of intranasal esketamine plus an oral antidepressant in participants with
treatment-resistant depression (TRD).